Compare Logitech International SA (LOGI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs TransMedics Group Inc — how do they compare? Logitech International SA trades at $98.27 (market cap $14.46B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Logitech International SA is far larger — about 5.3× TransMedics Group Inc's market cap, and Logitech International SA pays a 1.63% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and TransMedics Group Inc for 24 Days on average.
| LOGI | TMDX | |
|---|---|---|
Market Cap | $14.46B | $2.74B |
Volume | 349,547 | 949,331 |
Sector | Technology | Health |
52-Week High | $126.69 | $150.42 |
52-Week Low | $85.84 | $61.99 |
Typical Hold Time | 92 Days | 24 Days |
Enterprise Value | $12.79B | $3.13B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.50, down 0.67% on the day, with neutral technical indicators and mixed analyst sentiment. The company demonstrates strong profitability with 45.13% gross margins and 35.29% ROE, while recent earnings beats and new product launches including Zone Vibe Pro headsets and gaming partnerships signal innovation momentum. Cash flow trends show operational strength despite recent net outflow.
Outlook remains balanced with 5.3% upside to consensus price target of $107, though analyst ratings are evenly split. Key risks include chip shortage challenges cited by management and competitive pressures in the peripheral market. Revenue growth acceleration to $4.9B projected for 2026 supports potential valuation expansion if execution continues.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
